SCHEMBL2595963

SCHEMBL2595963

CCOC(=O)[C@H]1CC[C@H](c2nc(C)c(Br)s2)CC1

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 1/20 0.41
ALDH1A1 P00352 5/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 4/20 0.38
KDM4E B2RXH2 2/20 0.38
POLB P06746 2/20 0.38
TP53 P04637 1/20 0.38
NPC1 O15118 1/20 0.37
MAPK1 P28482 2/20 0.37
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2595965 1.00 PDK1 (0.41) PDK1ALDH1A1MEN1KMT2AGAA
SCHEMBL2595354 0.86 PDK1 (0.42) PDK1ALDH1A1MEN1KMT2AMAPT
SCHEMBL2595355 0.86 PDK1 (0.42) PDK1ALDH1A1MEN1KMT2AMAPT
SCHEMBL2589839 0.85 MAPT (0.42) PDK1ALDH1A1MEN1KMT2AGAA
SCHEMBL2589836 0.85 MAPT (0.42) PDK1ALDH1A1MEN1KMT2AGAA
SCHEMBL2595343 0.77 PDK1 (0.38) PDK1ALDH1A1KMT2AGAAMAPT
SCHEMBL22440659 0.76 KMT2A (0.44) ALDH1A1MEN1KMT2AGAAMAPT
SCHEMBL2589672 0.74 MAPT (0.42) PDK1ALDH1A1MEN1KMT2AGAA
SCHEMBL2589678 0.74 MAPT (0.42) PDK1ALDH1A1MEN1KMT2AGAA
SCHEMBL9234578 0.73 PDK1 (0.46) PDK1ALDH1A1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513238-B2 Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes HOFFMANN-LA ROCHE INC. (US) 2013-08-20 US disclosed
US-8513238-B2 Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes HOFFMANN-LA ROCHE INC. (US) 2013-08-20 US disclosed
EP-2569319-A1 HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES F.HOFFMANN-LA ROCHE AG (CH) 2013-03-20 EP disclosed
WO-2011141396-A1 HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES F. HOFFMANN-LA ROCHE AG (CH) 2011-11-17 WO disclosed
WO-2011141396-A1 HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES F. HOFFMANN-LA ROCHE AG (CH) 2011-11-17 WO disclosed
US-20110275801-A1 HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES HOFFMANN-LA ROCHE, INC. 2011-11-10 US disclosed
US-20110275801-A1 HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES HOFFMANN-LA ROCHE, INC. 2011-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275801-A1 HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES AVPR1A, AVPR1B, OXTR PDK1 2348/4885ALDH1A1 564/4885MEN1 1691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.